Med. Weter. 68 (5), 269-273, 2012

full text

pdf
Szyszko K., Pawłowski K.M., Majchrzak K., Mucha J. , Motyl T., Król M.
Drug delivery systems: Breakthroughs in cancer therapy with anthracyclines
Anthracyclines have commonly been used in the treatment of many cancers in humans and animals for more than two decades. Unfortunately, the cardiotoxicity of these drugs and a mechanism of chemoresistance to anthracyclines are the main factors limiting their use. Drug delivery systems (DDS) are of great promise in cancer therapy because they transport anthracyclines to cancer cells via endocytosis. Drugs transported with delivery systems are also less toxic. The best-studied drug carriers are liposomes, micelles, dendrimers, as well as polymeric and viral nanoparticles. They increase the apoptosis/necrosis of cancer cells, but the drugs are less toxic to normal cells and tissues. Modern drug delivery systems can improve anticancer therapy in humans and in animals.
Keywords: anthracyclines, drug delivery system, liposomes, micelles, dendrimers, nanoparticles